Gentex announced the acquisition of BioConnect, a Toronto‑based biometric authentication firm, on November 17 2025. The transaction adds BioConnect’s multi‑modal authentication software platform to Gentex’s portfolio, extending the company’s reach into the security and access‑control industry.
While the financial terms of the deal were not disclosed, the acquisition aligns with Gentex’s broader strategy to diversify beyond its core automotive mirror business. BioConnect serves more than 1,500 customers, including eight of the top ten U.S. data‑center operators, and offers a platform that integrates iris, facial, and behavioral biometrics.
The integration will pair BioConnect’s software with Gentex’s EyeLock iris technology, which was acquired earlier in the year through the purchase of VOXX International. Together, the companies will form a new Security & Access Control team, aiming to deliver end‑to‑end hardware‑software solutions for physical and digital identity verification.
Management highlighted that biometrics are increasingly important across Gentex’s existing markets—automotive, aerospace, medical—and that the acquisition positions the company to capture growth in the security sector. COO and CTO Neil Boehm emphasized that the move strengthens Gentex’s ability to develop advanced biometric solutions for its current customers.
Gentex reported Q3 2025 results on October 24, showing consolidated net sales of $655.2 million, up 8% from Q3 2024, while core automotive revenue fell 6% year‑over‑year. The acquisition is expected to offset the decline in core segments by adding a high‑margin, recurring‑revenue business.
The deal signals Gentex’s commitment to expanding its technology portfolio and diversifying revenue streams. By combining BioConnect’s software with its optical hardware, Gentex can offer integrated biometric solutions, potentially opening new markets and strengthening its competitive position in both legacy and emerging sectors.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.